Original article
General thoracic
Results of Initial Operations in Non–Small Cell Lung Cancer Patients With Single-Level N2 Disease

https://doi.org/10.1016/j.athoracsur.2005.08.018Get rights and content

Background

There is still debate regarding the use of surgery in the management of non–small cell lung cancer patients with N2 disease. The primary aim of the present study was analysis of the results of initial operations in non–small cell lung cancer patients with single-level N2 disease.

Methods

Ninety-four patients with the disease who underwent initial surgery consisting of complete resection of the primary site plus systematic lymphadenectomy were examined. We also immunohistochemically examined lymphatic vessel density and vascular endothelial growth factor-C expression.

Results

The overall 5- and 10-year survival rates for the 94 patients were 27.1% and 12.1%, respectively, with a median survival of 22 months. When stratified by skipping status, the 5-year survival rates for the patients in skip-N2 and non–skip-N2 groups were 33.4% and 19.8%, respectively (p = 0.0189). Skip metastasis, T factor, subcarinal lymph node metastasis, and adjuvant chemotherapy were recognized as independent prognostic indicators. In both skip-N2 and non–skip-N2 groups, distant relapse was the dominant pattern of recurrence. Although the peritumoral lymphatic vessel density was associated with vascular endothelial growth factor-C expression in tumors, the lymphangiogenic profile appeared to be different between skip-N2 and non–skip-N2 tumors, suggesting different nodal metastatic process.

Conclusions

Lung cancer patients with single-level N2 disease are an oncologically heterogeneous cohort. Although further studies involving randomized comparisons are required, the poor outcomes found here indicate that the initial operation has yet to be validated for patients with this disease.

Section snippets

Patients

Among 1,751 primary non–small cell lung cancer patients who underwent operations at Kanazawa University Hospital between January 1981 and May 2004, 325 patients were diagnosed as having mediastinal nodal involvement after resection of the primary site with systematic nodal dissection of both the hilar and mediastinal lymph nodes. Of those with N2 disease, 94 patients (52 men and 42 women) with a median age of 67 years (range, 36 to 82 years) had single-level N2 disease. All of these 94 patients

Results

The upper lobe was more frequently the primary site in the skip-N2 group as compared with the non–skip-N2 group (p = 0.0041). There were no significant differences in sex, age, tumor size, location of the primary site (right versus left), histologic type, percentage of patients with postoperative adjuvant therapy (systemic chemotherapy with or without radiation therapy), pathologic stage (IIIA versus IIIB), or the number of patients with clinical N2 disease between the two groups (Table 1).

With

Comment

In the present study, a relatively regular distribution of the spread of mediastinal nodal metastasis was found in both the skip and non–skip groups. That is, if the primary tumor was located in the upper lobe, nodal metastasis was detected mainly in the upper mediastinal area, whereas in patients with the primary tumor in the left lower lobe, nodal involvement was detected frequently in the lower mediastinal area. However, 7 patients (19.4% of the patients in whom the primary site was located

References (32)

Cited by (41)

  • Is there a survival difference between single station and multi-station N2 disease in operated non-small cell lung cancer patients?

    2015, Cancer Treatment Communications
    Citation Excerpt :

    The incidence of pathological N2 following surgical resection and complete mediastinal lymph node dissection varies from 17.6% to 26.5% [12], and the incidence of N2 was found 13.8% in our series. The involvement of a single station and the involvement of the lymph nodes other than the subcarinal lymph node are from the good prognostic criteria in N2 patients [13–16]. Several studies have demonstrated that the multiple-lymph node metastasis is a poor prognostic factor [8,9,17–19].

  • Prognostic factors after complete resection of pN2 non-small cell lung cancer

    2013, Journal of Thoracic and Cardiovascular Surgery
    Citation Excerpt :

    Skip N2 metastasis is discontinuous spread of tumors to mediastinal lymph nodes without involvement of the hilar lymph nodes. The incidence of lymph node skipping has been reported to be approximately 30% (22%-50%),5,6,15,17-21,23 and that of our study (50.0%) was slightly higher than these previous reports, which was likely due to a bias resulting from the fact that 60% of our patients had cN0 tumors. Several studies have reported that patients with skip N2 metastasis showed better prognosis than those with nonskip N2 metastasis5,6,15,19; however, other reports with contradictory findings also exist.20,21

  • Impact of the 7th TNM staging lung cancer in surgery

    2012, Journal of Infection and Public Health
    Citation Excerpt :

    This well clear confusion with large nodal masses that transgress individual nodal stations. Areas of continuing controversy regarding the relationship between lymph nodes metastases and overall survival include: intranodal versus extranodal disease [22]; single versus multiple (either N1 or N2) lymph node station disease [23–30]; the specific sites of lymph node metastases in relationship to the location of the primary tumor [24,26,29]; the significance of skip metastases [23]; and the need for systematic lymph node dissection versus a less extensive lymph node sampling [31] especially for tumors less than 2 cm in size [32]. Analyses of the IASLC database suggested that left upper lobe tumors with skip metastases in the AP zone (levels 5 and 6) were associated with a more favorable prognosis than other N2 subsets.

  • Implications of New (Seventh) TNM Classification of Lung Cancer on General Radiologists-A Pictorial Review

    2011, Current Problems in Diagnostic Radiology
    Citation Excerpt :

    For reconciliation of the 2 systems, lymph nodes were grouped into different zones and then analyzed to evaluate the prognosis of single- vs multilevel N1 and N2 disease. Previous studies have shown that skip metastases and single-level N2 disease (Fig 12) are both associated with better survival rates than involvement of multiple N2 lymph node stations (Fig 13).13,18-24 IASLC also had similar findings whereby single zone N2 disease had a similar survival to patients with multiple zone N1 disease, but the numbers were not statistically significant to warrant change in nodal descriptors.9

View all citing articles on Scopus
View full text